Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1992 May;30(5):1256–1261. doi: 10.1128/jcm.30.5.1256-1261.1992

Protein composition of the hepatitis B virus e antigen in the natural course of disease and following interferon therapy.

M L Campillo 1, J A Quiroga 1, J Bartolomé 1, G Moraleda 1, I Castillo 1, V Carreño 1
PMCID: PMC265260  PMID: 1374762

Abstract

The protein composition of hepatitis B virus (HBV) e antigen (HBeAg) in serum was analyzed for 63 viremic patients with chronic HBV and found to consist of polypeptides with molecular masses of 16, 18, and 20 kDa (P16e, P18e, and P20e, respectively). Several experiments demonstrated their viral nature and HBeAg specificity and that P16e occurs either in free soluble form or as aggregates or immunocomplexes, while P18e and P20e occur essentially as immunocomplexes. Of 63 patients, 45 (71%) had P16e, P18e, and P20e, and the remaining 18 (29%) had only P16e. During the natural history of the disease, spontaneous clearance of HBV DNA and HBeAg took place only in six of nine (67%) patients with the three HBe polypeptides but in none of the five patients having P16e alone (P less than 0.05). Similarly, 22 of 23 (96%) patients responding to interferon therapy had P16e, P18e, and P20e, but these polypeptides occurred in only 14 of 26 (54%) nonresponder patients (P less than 0.001). Following the loss of HBV DNA and HBeAg, before the development of anti-HBe, the only HBe species detected were P18e and P20e, but these became no longer detectable after complete normalization of liver function tests. Therefore, persistence of P16e represents a failure to recover from HBV, and the appearance of HBe polypeptides P18e and P20e is associated with virus clearance and a favorable outcome of the disease.

Full text

PDF
1256

Images in this article

1258Image
on p.1258
1258Image
on p.1258
1259Image
on p.1259
1259Image
on p.1259
1259Image
on p.1259

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baba K., Ise I., Aihara S., Kishimoto S., Tsuda F., Tachibana K., Miyakawa Y., Mayumi M. Small and large forms of hepatitis B e antigen in the serum: determination by two-site sandwich radioimmunoassay with monoclonal antibodies. Clin Exp Immunol. 1986 May;64(2):295–301. [PMC free article] [PubMed] [Google Scholar]
  2. Berninger M., Hammer M., Hoyer B., Gerin J. L. An assay for the detection of the DNA genome of hepatitis B virus in serum. J Med Virol. 1982;9(1):57–68. doi: 10.1002/jmv.1890090109. [DOI] [PubMed] [Google Scholar]
  3. Bredehorst R., von Wulffen H., Granato C. Quantitation of hepatitis B virus (HBV) core antigen in serum in the presence of antibodies to HBV core antigen: comparison with assays of serum HBV DNA, DNA polymerase, and HBV e antigen. J Clin Microbiol. 1985 Apr;21(4):593–598. doi: 10.1128/jcm.21.4.593-598.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bruss V., Gerlich W. H. Formation of transmembraneous hepatitis B e-antigen by cotranslational in vitro processing of the viral precore protein. Virology. 1988 Apr;163(2):268–275. doi: 10.1016/0042-6822(88)90266-8. [DOI] [PubMed] [Google Scholar]
  5. Carreño V., Porres J. C., Mora I., Bartolomé J., Bas C., Gutiez J., Cortés J., Hernández Guio C. Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon. Liver. 1987 Dec;7(6):325–332. doi: 10.1111/j.1600-0676.1987.tb00363.x. [DOI] [PubMed] [Google Scholar]
  6. Castillo I., Bartolomé J., Quiroga J. A., Porres J. C., Carreño V. Detection of HBeAg/anti-HBe immune complexes in the reactivation of hepatitis B virus replication among anti-HBe chronic carriers. Liver. 1990 Apr;10(2):79–84. doi: 10.1111/j.1600-0676.1990.tb00440.x. [DOI] [PubMed] [Google Scholar]
  7. Ganem D., Varmus H. E. The molecular biology of the hepatitis B viruses. Annu Rev Biochem. 1987;56:651–693. doi: 10.1146/annurev.bi.56.070187.003251. [DOI] [PubMed] [Google Scholar]
  8. Garcia P. D., Ou J. H., Rutter W. J., Walter P. Targeting of the hepatitis B virus precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage translocation can be aborted and the product released into the cytoplasm. J Cell Biol. 1988 Apr;106(4):1093–1104. doi: 10.1083/jcb.106.4.1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hoofnagle J. H., Dusheiko G. M., Seeff L. B., Jones E. A., Waggoner J. G., Bales Z. B. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med. 1981 Jun;94(6):744–748. doi: 10.7326/0003-4819-94-6-744. [DOI] [PubMed] [Google Scholar]
  10. Hoofnagle J. H., Peters M., Mullen K. D., Jones D. B., Rustgi V., Di Bisceglie A., Hallahan C., Park Y., Meschievitz C., Jones E. A. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology. 1988 Nov;95(5):1318–1325. doi: 10.1016/0016-5085(88)90367-8. [DOI] [PubMed] [Google Scholar]
  11. Imai M., Nomura M., Gotanda T., Sano T., Tachibana K., Miyamoto H., Takahashi K., Toyama S., Miyakawa Y., Mayumi M. Demonstration of two distinct antigenic determinants on hepatitis B e antigen by monoclonal antibodies. J Immunol. 1982 Jan;128(1):69–72. [PubMed] [Google Scholar]
  12. Lengyel P. Biochemistry of interferons and their actions. Annu Rev Biochem. 1982;51:251–282. doi: 10.1146/annurev.bi.51.070182.001343. [DOI] [PubMed] [Google Scholar]
  13. McLachlan A., Milich D. R., Raney A. K., Riggs M. G., Hughes J. L., Sorge J., Chisari F. V. Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences. J Virol. 1987 Mar;61(3):683–692. doi: 10.1128/jvi.61.3.683-692.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Milich D. R., McLachlan A., Moriarty A., Thornton G. B. Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J Immunol. 1987 Aug 15;139(4):1223–1231. [PubMed] [Google Scholar]
  15. Milich D. R., McLachlan A., Raney A. K., Houghten R., Thornton G. B., Maruyama T., Hughes J. L., Jones J. E. Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4348–4352. doi: 10.1073/pnas.88.10.4348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mora I., Porres J. C., Bartolomé J., Quiroga J. A., Gutiez J., Hernández Guio C., Bas C., Carreño V. Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection. J Hepatol. 1987 Feb;4(1):29–36. doi: 10.1016/s0168-8278(87)80006-5. [DOI] [PubMed] [Google Scholar]
  17. Ou J. H., Laub O., Rutter W. J. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1578–1582. doi: 10.1073/pnas.83.6.1578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pignatelli M., Waters J., Brown D., Lever A., Iwarson S., Schaff Z., Gerety R., Thomas H. C. HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology. 1986 May-Jun;6(3):349–353. doi: 10.1002/hep.1840060303. [DOI] [PubMed] [Google Scholar]
  19. Pignatelli M., Waters J., Lever A., Iwarson S., Gerety R., Thomas H. C. Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection. J Hepatol. 1987 Feb;4(1):15–21. doi: 10.1016/s0168-8278(87)80004-1. [DOI] [PubMed] [Google Scholar]
  20. Salfeld J., Pfaff E., Noah M., Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol. 1989 Feb;63(2):798–808. doi: 10.1128/jvi.63.2.798-808.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Takahashi K., Machida A., Funatsu G., Nomura M., Usuda S., Aoyagi S., Tachibana K., Miyamoto H., Imai M., Nakamura T. Immunochemical structure of hepatitis B e antigen in the serum. J Immunol. 1983 Jun;130(6):2903–2907. [PubMed] [Google Scholar]
  22. Takahashi K., Miyakawa Y., Gotanda T., Mishiro S., Imai M., Mayumi M. Shift from free "small" hepatitis B e antigen to IgG-bound "large" form in the circulation of human beings and a chimpanzee acutely infected with hepatitis B virus. Gastroenterology. 1979 Dec;77(6):1193–1199. [PubMed] [Google Scholar]
  23. Twu J. S., Lee C. H., Lin P. M., Schloemer R. H. Hepatitis B virus suppresses expression of human beta-interferon. Proc Natl Acad Sci U S A. 1988 Jan;85(1):252–256. doi: 10.1073/pnas.85.1.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Uy A., Bruss V., Gerlich W. H., Köchel H. G., Thomssen R. Precore sequence of hepatitis B virus inducing e antigen and membrane association of the viral core protein. Virology. 1986 Nov;155(1):89–96. doi: 10.1016/0042-6822(86)90170-4. [DOI] [PubMed] [Google Scholar]
  25. Yamada E., Ishida N., Ohori H. Comparison of the antigenicity and protein composition of hepatitis B virus e antigen subtypes HBeAg/1 and HBeAg/2. J Gen Virol. 1983 Apr;64(Pt 4):895–903. doi: 10.1099/0022-1317-64-4-895. [DOI] [PubMed] [Google Scholar]
  26. Yamada G., Takaguchi K., Matsueda K., Nishimoto H., Takahashi M., Fujiki S., Mizuno M., Kinoyama S., Tsuji T. Immunoelectron microscopic observation of intrahepatic HBeAg in patients with chronic hepatitis B. Hepatology. 1990 Jul;12(1):133–140. doi: 10.1002/hep.1840120121. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES